STCUBE Logo

STCUBE

Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.

052020 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 511 2201(삼성동, 무역센터 트레이드타워), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

STCube is a clinical-stage biopharmaceutical company specializing in the development of first-in-class, precision-driven immunotherapies for cancer. The company's core focus is on its lead drug candidate, Nelmastobart, the world's first immune checkpoint inhibitor targeting the novel BTN1A1 protein. This target is highly expressed in chemo-refractory and resistant cancer cells, often in a mutually exclusive manner with PD-L1, offering a new therapeutic avenue for patients with unmet medical needs. Having successfully completed Phase 1 clinical trials confirming its safety and efficacy, Nelmastobart represents a potential treatment for various treatment-resistant cancers. STCube advances its pipeline through research, development, and biomarker-driven clinical trials, collaborating with leading global institutions and forming strategic partnerships with multinational pharmaceutical companies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for STCUBE and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all STCUBE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for STCUBE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.